Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
90Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.12B | $1.31B | $5.66 |
| 2024 | $5.92B | $1.08B | $4.54 |
| 2023 | $5.58B | $1.01B | $4.09 |
| 2022 | $5.45B | $1.03B | $4.03 |
| 2021 | $4.77B | $728.00M | $2.80 |
Social Signal Score
Earnings
Wed, Feb 24(in 6 months)
Consensus estimate $3.18 per share
Typical surprise -5.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$3.23 vs $3.13beat
- Wed, Feb 25$3.92 vs $3.00beat
- Wed, Jul 30$2.78 vs $3.00miss
- Wed, Feb 26$2.48 vs $2.62miss
- Wed, Oct 30$2.28 vs $2.52miss
- Tue, Apr 30$2.38 vs $2.46miss
Estimates and results for WOLTF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from WOLTF's reported EPS growth of 19.2% a year over 4 years.
- EPS in 5 years
- $13.62
- Implied price
- $217.94
- Return from $80.50
- 22.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $108.35 — today's price is already 25.7% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 14 | 16 | 18 | 20 |
|---|---|---|---|---|---|
| 9.2% | 5.6% | 8.9% | 11.8% | 14.5% | 16.9% |
| 14.2% | 10.4% | 13.8% | 16.9% | 19.7% | 22.3% |
| 19.2% | 15.2% | 18.8% | 22.0% | 25.0% | 27.6% |
| 24.2% | 20.1% | 23.8% | 27.2% | 30.2% | 33.0% |
| 29.2% | 24.9% | 28.8% | 32.3% | 35.4% | 38.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newsbusinesswire.com·4d ago·Negative
Wolters Kluwer Brings Trusted Medi-Span Medication Intelligence to Growing Veterinary Drug Market WALTHAM, Mass.--(BUSINESS WIRE)-- #AI--Wolters Kluwer Health today announced the availability of Medi-Span® Vet Meds, an embedded drug data and screening solution to help U.S. pharmacies seamlessly expand to serve pet owners by providing veterinary prescriptions at the same place where they pick up their own medications. Built specifically for retail pharmacies, pharmacy partners, and veterinary med
View source ↗